Drug-induced Liver Injury in Latin America: 10-year Experience of the Latin American DILI (LATINDILI) Network

Bessone F.; Hernandez N.; Medina-Caliz I.; García-Cortés M.; Schinoni M.I.; Mendizabal M.; Chiodi D.; Nunes V.; Ridruejo E.; Pazos X.; Santos G.; Fassio E.; Parana R.; Reggiardo V.; Tanno H.; Sanchez A.; Tanno F.; Montes P.; Tagle M.; Arrese M.; Brahm J.; Girala M.; Lizarzabal M.I.; Carrera E.; Zerega A.; Bianchi C.; Reyes L.; Arnedillo D.; Cordone A.; Gualano G.; Jaureguizahar F.; Rifrani G.; Robles-Díaz M.; Ortega-Alonso A.; Pinazo-Bandera J.M.; Stephens C.; Sanabria-Cabrera J.; Bonilla-Toyos E.; Niu H.; Alvarez-Alvarez I.; Lucena M.I.; Andrade R.J. · Clinical Gastroenterology and Hepatology (2025) · DOI: 10.1016/j.cgh.2024.06.030

Resumen

Background & Aims: Latin America is a region of great interest for studying the clinical presentation of idiosyncratic drug-induced liver injury (DILI). A comprehensive analysis of patients enrolled into the LATINDILI Network over a decade is presented. Methods: Demographics, clinical presentation, histological findings and outcome of prospectively recruited DILI cases in the LATINDILI Network were analyzed. Suspected culprit drugs were classified according to the Anatomical Therapeutic Chemical classification. Causality was assessed using the Roussel Uclaf Causality Assessment Method (RUCAM) scale. Results: Overall, 468 idiosyncratic DILI cases were analyzed (62% women; mean age, 49 years). Hepatocellular injury predominated (62%); jaundice was present in 60% of patients, and 42% were hospitalized. Of the cases, 4.1% had a fatal outcome, and 24 patients (12%) developed chronic DILI. The most common drug classes were systemic anti-infectives (31%), musculoskeletal agents (12%), antineoplastic and immunomodulating agents (11%), and herbal and dietary supplements (9%). Notably, none of the patients with DILI due to antibacterials or immunosuppressants had a fatal outcome. In fact, Hy's law showed to have drug-specific predictive value, with anti-tuberculosis drugs, nimesulide, and herbal and dietary supplements associated with the worst outcome, whereas DILI caused by amoxicillin-clavulanate, nitrofurantoin, and diclofenac, which fulfilled Hy's law, did not have a fatal outcome. Conclusion: Features of DILI in Latin America are comparable to other prospective registries. However, the pattern of drugs responsible for DILI differs. An increasing incidence of herbal and dietary supplements, with high mortality rate, and likewise, nimesulide and nitrofurantoin, was noted. Thus, public health policies should raise awareness of the potential adverse effects of these compounds.